IL150485A0 - Method of achieving persistent transgene expression - Google Patents

Method of achieving persistent transgene expression

Info

Publication number
IL150485A0
IL150485A0 IL15048500A IL15048500A IL150485A0 IL 150485 A0 IL150485 A0 IL 150485A0 IL 15048500 A IL15048500 A IL 15048500A IL 15048500 A IL15048500 A IL 15048500A IL 150485 A0 IL150485 A0 IL 150485A0
Authority
IL
Israel
Prior art keywords
transgene expression
persistent transgene
achieving persistent
achieving
expression
Prior art date
Application number
IL15048500A
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL150485A0 publication Critical patent/IL150485A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL15048500A 1999-12-28 2000-12-27 Method of achieving persistent transgene expression IL150485A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47301899A 1999-12-28 1999-12-28
PCT/EP2000/013297 WO2001048231A2 (en) 1999-12-28 2000-12-27 Method of achieving persistent transgene expression

Publications (1)

Publication Number Publication Date
IL150485A0 true IL150485A0 (en) 2002-12-01

Family

ID=23877847

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15048500A IL150485A0 (en) 1999-12-28 2000-12-27 Method of achieving persistent transgene expression

Country Status (8)

Country Link
EP (1) EP1242608A2 (en)
JP (1) JP2003522133A (en)
CN (2) CN1310679C (en)
AU (1) AU3164801A (en)
CA (1) CA2395544A1 (en)
IL (1) IL150485A0 (en)
NZ (1) NZ531527A (en)
WO (1) WO2001048231A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223718B2 (en) * 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
CN101495498B (en) * 2005-02-07 2013-09-18 基因信息公司 Mild osteoarthritis biomarkers and uses thereof
US20070225233A1 (en) * 2006-03-27 2007-09-27 Tsu-Fuh Yeh Reducing the risk of chronic lung disease in infants
CN113384705A (en) * 2021-06-28 2021-09-14 西南大学 Preparation of poloxamer modified liposome and application of poloxamer modified liposome in oral drug delivery

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0465529B1 (en) * 1989-03-21 1998-04-29 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
EP1181937A3 (en) * 1994-08-09 2004-02-04 Cytrx Corporation Novel vaccine adjuvant and vaccine
US5633227A (en) * 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
EP0804076A4 (en) * 1994-10-19 1998-10-21 Genetic Therapy Inc Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6353055B1 (en) * 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
WO1996015780A1 (en) * 1994-11-23 1996-05-30 Isis Pharmaceuticals, Inc. Compositions and methods for preventing and treating allograft rejection
MY134778A (en) * 1995-10-23 2007-12-31 Hyal Pharmaceutical Australia Ltd Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization
DE19711800A1 (en) * 1997-03-21 1998-09-24 Hoechst Ag Extension of expression of transgenic proteins by immunomodulating treatment
ATE321882T1 (en) * 1997-07-01 2006-04-15 Isis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR ADMINISTRATION OF OLIGONUCLEOTIDES VIA THE ESOPHAUS

Also Published As

Publication number Publication date
CA2395544A1 (en) 2001-07-05
CN101011584A (en) 2007-08-08
CN1310679C (en) 2007-04-18
EP1242608A2 (en) 2002-09-25
NZ531527A (en) 2005-10-28
CN1433477A (en) 2003-07-30
AU3164801A (en) 2001-07-09
WO2001048231A2 (en) 2001-07-05
JP2003522133A (en) 2003-07-22
WO2001048231A3 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
AU3867400A (en) Methods of using bioelastomers
GB2351661B (en) Novel method of treatment
IL145875A0 (en) Novel method of treatment
IL146769A0 (en) Method of sterilizing
HK1042852A1 (en) Method of enhancing insulin action
IL141362A0 (en) Method of performing transgenesis
IL150485A0 (en) Method of achieving persistent transgene expression
AU3047299A (en) Methods of delivering glp-1
GB2389182B (en) Method of purifying b-secretase
GB9930688D0 (en) Novel method of treatment
GB9924752D0 (en) Method of construction
PL341752A1 (en) Method of obtaining aryloamino hydroxyantraquinones
AU8031700A (en) Method of treating fibrosis
AU1751900A (en) Eosinophil-specific expression of transgenes
PL336550A1 (en) Method of decoposing 2-chloroethenylchloroarsazine
GB9930696D0 (en) Novel method of treatment
GB9921221D0 (en) Method of controlling weeds
TW420365U (en) Improved structure of stabilizer
PL333334A1 (en) Method of obtaining silylethenes
TW388282U (en) Improved structure of goggles
AUPQ372099A0 (en) Method of cryopreservation
PL331683A1 (en) Method of obtaining sulphoxides
GB9901310D0 (en) Methods of treatment
GB9917181D0 (en) Methods of treatment
TJ99000556A (en) Method of treatment of nevrodermite